Showing results (681-690 of 709) with videos related to

Sort By:
Pageof 71
Lancet (London, England)|May 11, 2025
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trialThomas Yau, Peter R Galle, Thomas Decaens, et al.
Future Oncology (London, England)|September 6, 2023
Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)Ghassan K Abou-Alfa, George Lau, Masatoshi Kudo, et al.
NEJM Evidence|February 6, 2024
Tremelimumab plus Durvalumab in Unresectable Hepatocellular CarcinomaGhassan K Abou-Alfa, George Lau, Masatoshi Kudo, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 20, 2022
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinomaMathew Vithayathil, Antonio D'Alessio, Claudia A M Fulgenzi, et al.
Hepatology International|April 3, 2023
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinomaMathew Vithayathil, Antonio D'Alessio, Claudia Angela Maria Fulgenzi, et al.
JHEP Reports : Innovation in Hepatology|December 1, 2025
Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN studyPasquale Lombardi, Jung Sun Kim, Giulia F Manfredi, et al.
World Journal of Gastrointestinal Oncology|December 11, 2023
Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinomaSirish Dharmapuri, Umut Özbek, Hiren Jethra, et al.
Gastroenterology|September 15, 2022
Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular CarcinomaPhilipp K Haber, Florian Castet, Miguel Torres-Martin, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|December 28, 2022
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational studyThomas Talbot, Antonio D'Alessio, Matthias Pinter, et al.
Hepatology (Baltimore, Md.)|March 21, 2022
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world studyAntonio D'Alessio, Claudia Angela Maria Fulgenzi, Naoshi Nishida, et al.
Pageof 71